Pursuant to article L-223-8 II of the French code de Commerce and 223-16 of the AMF’s General Regulations.
SOPHIA ANTIPOLIS, France–(BUSINESS WIRE)–Regulatory News:
Median Technologies (Paris:ALMDT):
|
Total (EPA:) number of shares |
18,516,983 |
|
Number of real voting rights (excluding treasury shares) |
18,452,795 |
|
Theoretical number of voting rights (including treasury shares) |
18,493,783 |
() Class E preference shares are non-voting
() pursuant to article 223-11 of the AMF’s General Regulations
About Median Technologies: Pioneering innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median’s offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis™, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext (EPA:) Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit www.mediantechnologies.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241112243576/en/
Median Technologies
Emmanuelle Leygues
VP, Corporate Marketing & Financial Communications
+33 6 10 93 58 88
emmanuelle.leygues@mediantechnologies.com
Press – ALIZE RP
Caroline Carmagnol
+33 6 64 18 99 59
median@alizerp.com
Investors – ACTIFIN
Ghislaine Gasparetto
+33 6 21 10 49 24
ghislaine.gasparetto@seitosei-actifin.com
Source: Median Technologies
